NASDAQ:RDNT - RadNet Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $13.13 -0.11 (-0.83 %) (As of 05/19/2019 02:19 AM ET)Previous Close$13.13Today's Range$13.08 - $13.6752-Week Range$9.97 - $16.54Volume249,585 shsAverage Volume324,683 shsMarket Capitalization$657.55 millionP/E Ratio19.89Dividend YieldN/ABeta1.16 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the imaging industry, including picture archiving communications systems; and provides teleradiology services for remote interpretation of images on behalf of radiology groups, hospitals, and imaging center customers. As of December 31, 2017, it operated 297 facilities directly or indirectly through joint ventures with hospitals in California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California. Receive RDNT News and Ratings via Email Sign-up to receive the latest news and ratings for RDNT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RDNT Previous Symbol CUSIPN/A CIK790526 Webwww.radnet.com Phone310-478-7808Debt Debt-to-Equity Ratio4.74 Current Ratio0.72 Quick Ratio0.87Price-To-Earnings Trailing P/E Ratio19.89 Forward P/E Ratio37.51 P/E Growth5.04 Sales & Book Value Annual Sales$975.15 million Price / Sales0.67 Cash Flow$2.2142 per share Price / Cash Flow5.93 Book Value$4.26 per share Price / Book3.08Profitability EPS (Most Recent Fiscal Year)$0.66 Net Income$32.24 million Net Margins3.53% Return on Equity22.38% Return on Assets3.31%Miscellaneous Employees7,869 Outstanding Shares50,080,000Market Cap$657.55 million Next Earnings Date8/8/2019 (Estimated) OptionableOptionable RadNet (NASDAQ:RDNT) Frequently Asked Questions What is RadNet's stock symbol? RadNet trades on the NASDAQ under the ticker symbol "RDNT." How were RadNet's earnings last quarter? RadNet Inc. (NASDAQ:RDNT) issued its earnings results on Thursday, May, 9th. The medical research company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). The medical research company earned $271.50 million during the quarter, compared to analysts' expectations of $256.30 million. RadNet had a net margin of 3.53% and a return on equity of 22.38%. The business's revenue for the quarter was up 17.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.15) EPS. View RadNet's Earnings History. When is RadNet's next earnings date? RadNet is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for RadNet. What guidance has RadNet issued on next quarter's earnings? RadNet updated its FY 2019 earnings guidance on Thursday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.05-1.1 billion, compared to the consensus revenue estimate of $1.07 billion. What price target have analysts set for RDNT? 1 Wall Street analysts have issued 12-month price targets for RadNet's stock. Their forecasts range from $17.50 to $17.50. On average, they anticipate RadNet's share price to reach $17.50 in the next year. This suggests a possible upside of 33.3% from the stock's current price. View Analyst Price Targets for RadNet. What is the consensus analysts' recommendation for RadNet? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RadNet in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for RadNet. Has RadNet been receiving favorable news coverage? News stories about RDNT stock have trended negative this week, according to InfoTrie. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. RadNet earned a news impact score of -2.1 on InfoTrie's scale. They also gave news articles about the medical research company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. Who are some of RadNet's key competitors? Some companies that are related to RadNet include Genomic Health (GHDX), InVitae (NVTA), Natera (NTRA), CareDx (CDNA), Veracyte (VCYT), Celcuity (CELC), Enzo Biochem (ENZ), Fulgent Genetics (FLGT), Miragen Therapeutics (MGEN), PotNetwork (POTN), Psychemedics (PMD), Biocept (BIOC), Avant Diagnostics (AVDX), CBA Florida (CBAI) and First Choice Healthcare Solutions (FCHS). What other stocks do shareholders of RadNet own? Based on aggregate information from My MarketBeat watchlists, some companies that other RadNet investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Alibaba Group (BABA), UnitedHealth Group (UNH), Adobe (ADBE), Rigel Pharmaceuticals (RIGL), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Synergy Pharmaceuticals (SGYP) and Visa (V). Who are RadNet's key executives? RadNet's management team includes the folowing people: Dr. Howard G. Berger, Chairman, Pres, CEO & Treasurer (Age 73)Mr. Mark D. Stolper, Exec. VP & CFO (Age 48)Mr. Norman R. Hames, Pres, COO of Western Operations & Director (Age 63)Mr. Stephen M. Forthuber, Pres & COO of Eastern Operations (Age 58)Mr. Ranjan Jayanathan, Chief Information Officer & GM of Radiology Information Technology Division Who are RadNet's major shareholders? RadNet's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.15%), Moab Capital Partners LLC (4.55%), FMR LLC (3.96%), Renaissance Technologies LLC (3.69%), Dimensional Fund Advisors LP (3.17%) and Dalton Greiner Hartman Maher & Co. (2.39%). Company insiders that own RadNet stock include David L Swartz, Jeffrey L Linden, John V Crues, Lawrence L Levitt, Mark Stolper, Marvin S Cadwell, Michael L Md Sherman, Michael N Murdock, Norman R Hames, Sandy Nyholm Kaminsky and Stephen M Forthuber. View Institutional Ownership Trends for RadNet. Which major investors are selling RadNet stock? RDNT stock was sold by a variety of institutional investors in the last quarter, including Moab Capital Partners LLC, AQR Capital Management LLC, ClariVest Asset Management LLC, BlackRock Inc., Eqis Capital Management Inc., Wells Fargo & Company MN, Globeflex Capital L P and FMR LLC. Company insiders that have sold RadNet company stock in the last year include David L Swartz, Jeffrey L Linden, Mark Stolper, Michael L Md Sherman and Norman R Hames. View Insider Buying and Selling for RadNet. Which major investors are buying RadNet stock? RDNT stock was purchased by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co., Global Alpha Capital Management Ltd., Beck Mack & Oliver LLC, Royce & Associates LP, Candriam Luxembourg S.C.A., Victory Capital Management Inc., Geode Capital Management LLC and Tibra Equities Europe Ltd. View Insider Buying and Selling for RadNet. How do I buy shares of RadNet? Shares of RDNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is RadNet's stock price today? One share of RDNT stock can currently be purchased for approximately $13.13. How big of a company is RadNet? RadNet has a market capitalization of $657.55 million and generates $975.15 million in revenue each year. The medical research company earns $32.24 million in net income (profit) each year or $0.66 on an earnings per share basis. RadNet employs 7,869 workers across the globe. What is RadNet's official website? The official website for RadNet is http://www.radnet.com. How can I contact RadNet? RadNet's mailing address is 1510 COTNER AVE, LOS ANGELES CA, 90025. The medical research company can be reached via phone at 310-478-7808 or via email at [email protected] MarketBeat Community Rating for RadNet (NASDAQ RDNT)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 245 (Vote Outperform)Underperform Votes: 226 (Vote Underperform)Total Votes: 471MarketBeat's community ratings are surveys of what our community members think about RadNet and other stocks. Vote "Outperform" if you believe RDNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDNT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: What is a put option? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.